跳至主要内容
临床试验/NCT05129384
NCT05129384终止不适用

Colonization of the Infant Gut With B. Infantis EVC001 to Reduce Symptoms of Colic

Evolve BioSystems, Inc.2 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2022年2月23日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
入组人数
1
试验地点
2
主要终点
Change in crying/fussing duration

研究概览

简要总结

To investigate whether B. infantis EVC001 colonization in the infant gut can reduce symptoms of colic

详细描述

There is evidence to support that B. infantis EVC001 supplementation may ameliorate symptoms associated with colic by establishing and maintaining the necessary gut microbial composition to promote proper barrier and immune function in infants. The primary objective of this study is to assess the effect of the probiotic, B. infantis EVC001, on reducing the duration of crying/fussing symptoms of breastfed infants diagnosed with infantile colic from Baseline to Day 14.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

This is a double-blind, randomized, placebo-controlled study

入排标准

年龄范围
14 Days 至 42 Days(Child)
性别
All
接受健康志愿者

入选标准

  • Infants with a diagnosis of infantile colic per Rome IV criteria and reported to cry/fuss for ≥ 3 hours/day, within a 24-hour period as determined by the 24-hour cry/fuss eDiary AND 24 hours of LENA vocalizations
  • Infants with a gestational period of ≥ 37 to 42 weeks
  • Infants between 14 and ≤ 42 days of life at the completion of screening/baseline tasks
  • Infants exclusively breastfed for at least 7 days immediately prior to enrollment and with mother's intent to continue feeding breast milk exclusively for the duration of the study
  • Mothers willing to use their own electronic device(s) to download and utilize all required study software (decentralized trial platform on a mobile device and the LENA device software on a Windows 10 or higher laptop or desktop that has at least 10 GB of free space and fast, reliable internet)
  • Mother is fluent in English

排除标准

  • Infants born in multiple birth (i.e., twins, triplets, etc.)
  • Infants born with medical complications (i.e., neurological, cerebral palsy, confirmed food allergies)
  • Infants with current evidence of failure to thrive, fever, or illness
  • Infants with any GI tract abnormalities
  • Antibiotic, infant formula, solid food or iron supplement intake within 7 days prior to enrollment or mother's intent to feed non-study probiotics, prebiotics, infant formula, solid food or iron supplements to their infant at any time during the study
  • Infants who have consumed any probiotics since birth
  • Unwillingness to discontinue/avoid products used to treat IC (i.e., Simethicone, gripe water, colic drops, etc.) during the study. Note: consumption of IC products prior to the baseline period is NOT exclusionary
  • Maternal use of probiotics containing B. infantis during pregnancy, after the baby's birth and/or intent to use probiotics containing B. infantis at any time throughout the study
  • Maternal smoking or smoking within the home by any household member currently or during pregnancy
  • Mother following exclusionary diet due to her infant's colic (i.e., dairy elimination diet)
  • Any infant the Investigator deems to be ineligible for participation

结局指标

主要结局

Change in crying/fussing duration

时间窗: Baseline to Day 14

Assess the effect of the probiotic, B. infantis EVC001, on duration of crying/fussing symptoms of breastfed infants diagnosed with infantile colic

次要结局

未报告次要终点

研究者

发起方
Evolve BioSystems, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验